Results 111 to 120 of about 2,487,415 (296)

3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate

Advanced Science, EarlyView.
The blood–brain–tumor barrier (BBTB) penetration by anticancer drugs and their effects on glioblastoma (GBM) is assessed using 3D bioprinted‐spheroids. Anticancer drug‐induced U‐87 MG cell death is quantified through in situ imaging of spheroids using a cancer cell death probe. The Ru compound, a partial P‐gp substrate, induces greater tumor‐cell death
Hyunjung Lee, Chan Ho Jeon, Doyun Kim, Minjae Lee, Minji Kwon, Joon Myong Song   +5 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma

Molecular & Cellular Oncology
Cisplatin is the commonly used chemotherapeutic drug in treatment of various cancers. However, development of resistance towards cisplatin results in tumor recurrence.
Ankit P. Jain, Vivek Ghose, Srijon Munshi, Firdous A. Bhat, Gourav Dey, Vishalakshi Nanjappa   +5 more
doaj   +1 more source

SOX2 Inhibits Cuproptosis to Affect Cisplatin Resistance in Non-Small Cell Lung Cancer by Activating the Wnt/ATP7B Signaling Pathway. [PDF]

Kaohsiung J Med Sci
ABSTRACT Cisplatin (CDDP) resistance constitutes the principal clinical challenge in the treatment of advanced non‐small cell lung cancers (NSCLC). Disturbances in copper metabolism are closely linked with tumor drug resistance. SOX2, a pivotal stemness transcription factor (TF), holds an important role in chemotherapy resistance.
Chen K, He FM, Huang YH, Fang T, Zheng YP, Cai JF.   +5 more
europepmc   +2 more sources

ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study identifies ZMIZ2 as a therapeutic target for docetaxel‐resistant triple‐negative breast cancer, sustaining cancer stemness‐associated properties and docetaxel resistance. ZMIZ2 upregulation enhances DUX4‐mediated LGR5 activation through the SWI/SNF components BRG1 and BAF57.
Xueting Gan, Shulei Sun, Ran Hu, Yuheng Feng, Xinhao Wu, Fangqi Liu, Xuyong Lin, Xiupeng Zhang, Xuezhu Rong, Qiang Han   +9 more
wiley   +1 more source

Concurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT We report a patient with a pathogenic germline variant (PGV) in RB1 and somatic mosaicism for a pathogenic TP53 variant who developed three distinct types of childhood cancer: retinoblastoma, osteosarcoma, and myelodysplastic syndrome (MDS) before the age of 6 years.
Ole Haubjerg Nielsen, Ulrik Kristoffer Stoltze, Pernille Axél Gregersen, Marianne Hoffmann, Morten Lyng Høgild, Mette Klarskov Andersen, Lise Barlebo Ahlborn, Lisa Lyngsie Hjalgrim, Karin A. W. Wadt   +8 more
wiley   +1 more source

Liposomal drugs: approach to overcome drug resistance to cisplatin [PDF]

, 2009
В статье описаны причины возникновения лекарственной устойчивости к цисплатину. Дана характеристика липосомам как переносчикам лекарственных средств.
Носко, М.М., Пивнюк, В.М., Кулик, Г.И., Тодор, И.Н., Чехун, В.Ф.   +4 more
core   +2 more sources

Knockdown of TOP2A reverses cisplatin resistance in ovarian cancer by inhibiting EMT via ferroptosis mediated by the TP53/GPX4/SLC7A11 axis

Frontiers in Immunology
IntroductionCisplatin resistance is a major challenge in ovarian cancer therapy, particularly for high-grade serous ovarian cancer (HGSOC). DNA topoisomerase IIα (TOP2A) relates to cancer drug resistance, yet its role and molecular mechanisms in ovarian ...
Xinyue Liu, Xinyue Liu, Junxia Wang, Yangyu Liu, Yan Han, Zhichao Qin, Yu Wang, Shanxiang Gao, Xinghua Li, Yuping Suo   +9 more
doaj   +1 more source

CRISPR-Cas9 screening identifies ATOX1-driven cisplatin resistance mechanisms in liver cancer and evaluates targeted inhibitor efficacy

Communications Biology
Liver cancer treatment with cisplatin is often hindered by drug resistance. This study aimed to identify key genes associated with cisplatin resistance in liver cancer and develop targeted inhibitors.
Chujiao Hu, Huading Tai, Renguang Zhu, Zhengyu Shu, Guanghao Guo, Dan Ma, Shi Zuo, Lei Tang, Zhirui Zeng   +8 more
doaj   +1 more source

Generation of Cisplatin-Resistant Ovarian Cancer Cell Lines: Cisplatin Resistance in Ovarian Cancer Cell Lines

, 2016
Ovarian cancer is the most lethal gynecological cancer in which cisplatin-based treatment plays a fundamental role as the first line chemotherapy option.
Nastaran Nikounezhad, Farshad H. Shirazi, Maryam Nakhjavani   +2 more
core   +1 more source